Table 1. Clinical characteristics and KRAS mutation status in patients with pancreatic cancer.
| Characteristics | All patients (N=39), n (%) | KRAS genotype | P value | |
|---|---|---|---|---|
| Wild type (N=12), n (%) | Mutant (N=27), n (%) | |||
| Sex | 0.619538 | |||
| Male | 25 (64.1) | 7 (58.3) | 18 (66.7) | |
| Female | 14 (35.9) | 5 (41.7) | 9 (33.3) | |
| Age (years) | 0.317409 | |||
| ≤60 | 9 (23.0) | 4 (33.3) | 5 (18.5) | |
| ≥60 | 30 (77.0) | 8 (66.7) | 22 (81.4) | |
| Ethnicity | ||||
| African American | 6 (15.4) | 2 (16.7) | 4 (14.8) | 0.883195 |
| Caucasian | 32 (82.0) | 9 (75.0) | 23 (85.2) | 0.449136 |
| Unknown | 1 (2.6) | 1 (8.3) | 0 (0.0) | 0.137109 |
| ECOG performance status | ||||
| 0 | 19 (48.7) | 8 (66.7) | 11 (40.7) | 0.14339 |
| 1 | 18 (46.2) | 4 (33.3) | 14 (51.9) | 0.291242 |
| 2 | 2 (5.1) | 0 (0.0) | 2 (7.4) | 0.339352 |
| Stage | ||||
| I | 2 (5.1) | 2 (16.7) | 0 (0.0) | 0.035862 |
| IIA | 6 (15.4) | 1 (8.3) | 5 (18.5) | 0.421047 |
| IIB | 8 (20.5) | 2 (16.7) | 6 (22.2) | 0.693972 |
| III | 5 (12.8) | 1 (8.3) | 4 (14.8) | 0.579666 |
| IV | 18 (46.1) | 6 (50) | 12 (44.4) | 0.74986 |
| Differentiation | ||||
| Well | 0 (0.0) | 0 (0.0) | 0 (0.0) | – |
| Moderate | 11 (28.2) | 3 (25.0) | 8 (29.6) | 0.76848 |
| Poor | 23 (59.0) | 7 (58.3) | 16 (59.2) | 0.957022 |
| Undifferentiated | 1 (2.6) | 0 (0.0) | 1 (3.7) | 0.503633 |
| Unknown | 4 (10.2) | 2 (16.7) | 2 (7.4) | 0.384719 |
| Disease status | ||||
| Local-regional at diagnosis | 21 (53.8) | 6 (50.0) | 15 (55.6) | 0.74986 |
| Metastatic disease | 18 (46.2) | 6 (50.0) | 12 (44.4) | 0.74986 |
| First-line regimens | ||||
| Gemcitabine | 1 (2.6) | 0 (0.0) | 1 (3.7) | 0.503633 |
| Gemcitabine and nab-paclitaxel | 33 (84.6) | 9 (75.0) | 24 (88.9) | 0.27436 |
| FOLFIRINOX | 5 (12.8) | 3 (25.0) | 2 (7.4) | 0.137831 |
ECOG, Eastern Cooperative Oncology Group.